GSK (LON:GSK) Releases Quarterly Earnings Results

GSK (LON:GSK) issued its earnings results on Wednesday. The company reported GBX 23.20 ($0.29) earnings per share (EPS) for the quarter, Digital Look Earnings reports. GSK had a return on equity of 33.30% and a net margin of 12.83%.

GSK Stock Performance

LON:GSK opened at GBX 1,452 ($18.06) on Friday. The firm has a 50-day moving average of GBX 1,353.92 and a two-hundred day moving average of GBX 1,457.61. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. The stock has a market cap of £59.24 billion, a P/E ratio of 1,284.96, a PEG ratio of 1.24 and a beta of 0.31. GSK has a 1-year low of GBX 1,282.50 ($15.95) and a 1-year high of GBX 1,823.50 ($22.68).

Insider Transactions at GSK

In related news, insider Jonathan Symonds purchased 1,500 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was acquired at an average price of GBX 1,315 ($16.35) per share, for a total transaction of £19,725 ($24,530.53). Corporate insiders own 1.61% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th. Berenberg Bank decreased their price target on shares of GSK from GBX 1,820 ($22.63) to GBX 1,600 ($19.90) and set a “buy” rating for the company in a research report on Friday, November 29th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of GBX 1,805.83 ($22.46).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.